세계의 HTS(High Throughput Screening) 시장 : 시장 규모, 점유율, 동향-제공 제품별, 용도별, 기술별, 최종 사용자별, 지역별 - 예측(-2029년)
High Throughput Screening Market / HTS Market Size, Share & Trends by Offering (Instruments, Consumables, Software, Services), Technology, Application - Global Forecast to 2029
세계의 HTS(High Throughput Screening) 시장 규모는 2024년 288억 달러로 추정되고, 2029년 502억 달러에 이를 전망이며, 예측 기간 동안 CAGR은 11.8%로 예측됩니다.
제약 및 바이오기업은 학술기관, 연구기관, 기술공급자와 연계하여 HTS(High Throughput Screening)에서 외부 전문지식과 신기술을 이용할 수 있습니다. 예를 들어 2023년 ChemDiv, Inc.(미국)는 텍사스 대학 의학부(UTMB)와 제휴하여 재고를 확대하고 HTS 연구 프로그램을 진행하고 있습니다. 또한, 플로리다 대학 건강 학부(미국)와 같은 연구 기관은 분석 개발, 파일럿 스크리닝, HTS 캠페인 등 다양한 고처리량 스크리닝 용도에서 연구 그룹과 협력하고 있습니다. 마찬가지로 Novartis AG(스위스)와 같은 주요 제약 회사는 신약 후보를 발견하고 개발하기 위한 연구개발에 2023년에 36 억 4,000만 달러를 투자했습니다. 이 투자액은 전년 대비 24% 웃돌고 있습니다. 제약기업이나 연구기관에 의한 연구개발에 대한 자원배분이 증가함에 따라 HTS과 같은 효율적이고 효과적인 창약기술에 대한 수요가 높아질 것으로 보입니다.
| 조사 범위 |
| 조사 대상년도 |
2022-2029년 |
| 기준년 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 검토 단위 |
금액(달러) |
| 부문별 |
제공 제품별, 용도별, 기술별, 최종 사용자별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카(LATAM), 중동 및 아프리카 |
HTS 시장은 제공 제품별로 소모품, 장비, 서비스, 소프트웨어로 구분됩니다. HTS 시장에서의 서비스에는 고처리량 스크리닝 서비스, 분석 개발 서비스, 세포주 개발 서비스, 마이크로플레이트 개발 서비스가 포함됩니다. 이러한 서비스는 효과적인 창약 및 생명 과학 연구에 필요한 도구와 프로세스를 제공하므로 HTS(High Throughput Screening)에 필수적입니다. 의약품 및 히트 화합물 식별을 위한 분석의 복잡화, 비용 효율적이고 전문적인 HTS 전문 지식에 대한 수요 증가 등의 요인이 서비스 부문의 성장을 뒷받침하고 있습니다. 또한 서비스 제공업체는 연구 및 규제 위험을 줄이고 제약 회사 및 바이오 기술 기업이 핵심 역량에 집중할 수 있도록 지원합니다. 이러한 요인들로 인해 HTS 서비스 분야는 기업들에게 유익한 시장으로 떠오르고 있으며, 예측 기간 동안 시장에서 가장 높은 성장률을 기록했습니다.
최종 사용자별로, HTS 시장은 제약 및 바이오 기술 기업, 학술 및 연구 기관, CRO 및 기타 최종 사용자로 분할됩니다. 계약연구기관(CRO)은 예측기간 동안 가장 높은 성장률을 보일 것으로 예측됩니다. 이러한 성장은 제약기업이나 바이오기술기업이 CRO와 같은 연구기관에 연구개발 활동을 아웃소싱하는 경향이 강해지고 있는 것에 기인하고 있습니다. HTS(High Throughput Screening)를 통해 CRO는 특정 대상에 대한 화합물의 대규모 라이브러리를 신속하게 스크리닝할 수 있으므로 리드 화합물을 보다 효율적으로 탐색할 수 있습니다. 부적합한 화합물을 조기에 식별함으로써 CRO는 제약 회사의 고객 비용과 위험을 줄이고 시간과 비용을 절약하고 후기 단계에서 실패의 위험을 최소화할 수 있습니다. CRO는 첨단 HTS 기술과 인프라에 투자하고 있으며 중소기업에서는 실현할 수 없는 복잡한 스크리닝을 구현할 수 있습니다. 예를 들어 Labcorp의 의약품 개발 서비스는 로봇 스크리닝 시스템을 사용하고 Parexel은 AI와 머신러닝을 HTS에 통합하여 스크리닝 능력을 강화하고 있습니다.
본 보고서에서는 세계의 HTS(High Throughput Screening) 시장에 대해 조사했으며,, 제공 제품별, 용도별, 기술별, 최종 사용자별, 지역별 동향, 시장 진출기업 프로파일 등을 정리했습니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 중요 인사이트
제5장 시장 개요
- 서문
- 시장 역학
- 업계 동향
- 기술 분석
- 고객의 비즈니스에 영향을 미치는 동향 및 혼란
- 가격 분석
- 밸류체인 분석
- 공급망 분석
- 생태계 분석
- 특허 분석
- 무역 분석
- 규제 분석
- Porter's Five Forces 분석
- 주된 회의 및 이벤트(2024-2025년)
- 주요 이해관계자 및 구매 기준
제6장 HTS(High Throughput Screening) 시장 : 제공 제품별
제7장 HTS(High Throughput Screening) 시장 : 용도별
- 서문
- 창약
- 생화학 스크리닝
- 생명과학 연구
- 기타
제8장 HTS(High Throughput Screening) 시장 : 기술별
제9장 HTS(High Throughput Screening) 시장 : 최종 사용자별
- 서문
- 제약 및 바이오 기술 기업
- 학술연구기관
- CRO
- 기타
제10장 HTS 시장 : 지역별
- 서문
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제11장 경쟁 구도
- 개요
- 주요 진입기업의 전략 및 비책
- 수익 분석
- 시장 점유율 분석
- 기업평가 매트릭스 : 주요 진입기업(2023년)
- 기업평가 매트릭스 : 스타트업 및 중소기업(2023년)
- 기업평가 및 재무지표
- 브랜드 및 제품 비교
- 경쟁 시나리오
제12장 기업 프로파일
- 주요 진출기업
- THERMO FISHER SCIENTIFIC INC.
- AGILENT TECHNOLOGIES, INC.
- MERCK KGAA
- DANAHER CORPORATION
- REVVITY, INC.
- TECAN GROUP LTD.
- BIO-RAD LABORATORIES, INC.
- CORNING INCORPORATED
- METTLER-TOLEDO INTERNATIONAL INC.
- LONZA GROUP
- WATERS CORPORATION
- SARTORIUS AG
- EPPENDORF SE
- PORVAIR PLC
- GREINER AG
- CHARLES RIVER LABORATORIES
- EUROFINS SCIENTIFIC
- HAMILTON COMPANY
- AURORA BIOMED INC.
- GILSON INCORPORATED
- BRAND GMBH CO KG
- 기타 기업
- BMG LABTECH GMBH
- DIANA BIOTECHNOLOGIES, AS
- CREATIVE BIOLABS
- HIGHRES BIOSOLUTIONS
- BIOMAT SRL
- AXXAM SPA
- SYGNATURE DISCOVERY LIMITED
- CROWN BIOSCIENCE
제13장 부록
AJY
The global high-throughput screening market size is projected to reach USD 50.2 billion by 2029 from USD 28.8 billion in 2024, at a CAGR of 11.8% during the forecast period. Pharmaceutical & biotechnology companies collaborate with academic institutions, research organizations, and technology providers, enabling them to access external expertise and novel technologies in high-throughput screening (HTS). For instance, in 2023, ChemDiv, Inc. (US) collaborated with the University of Texas Medical Branch (UTMB) to expand its inventory and advance its high throughput screening (HTS) research programs. Furthermore, institutions such as the University of Florida Health (US) collaborate with research groups for various high-throughput screening applications, including assay development, pilot screening, and HTS campaigns. The university's High Throughput Molecular Screening Center supports researchers by providing grant support for their research Similarly, major pharmaceutical companies, such as Novartis AG (Switzerland), invested USD 3.64 billion in 2023, for exploratory research to discover and develop new drug candidates. This investment was 24% higher than the previous year's investment. With the increased allocation of resources to research and development by pharmaceutical companies and research institutions, there will be a growing demand for efficient and effective drug discovery technologies like high throughput screening (HTS).
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD) |
| Segments | By Offerings, Application, Technology, and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America (LATAM), Middle East and Africa |
"The services segment is set to register highest growth rate during 2024-2029 in the high throughput screening (HTS) market"
The high-throughput screening (HTS) offerings market is segmented into consumables, instruments, services, and software. Services in the high-throughput screening (HTS) market include high-throughput screening services, assay development services, cell line development services, and microplate development services. These services are essential for high-throughput screening as they offer tools and processes necessary for effective drug discovery and life science research. Factors such as increasing assay complexities for drug development and hit identification, along with the growing demand for cost-effective and specialized high-throughput screening (HTS) expertise drive the growth of the service segment. Service providers also help mitigate research and regulatory risks and allow pharmaceutical and biotechnology companies to focus on their core competencies. Owing to these factors, the high-throughput screening (HTS) services segment has emerged as a beneficial market space for companies and registered the highest growth rate in the market during the forecast period.
"CRO end user segment is set to witness the highest growth rate in the HTS market"
Based on end user, the high-throughput screening market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs), and other end users. Contract Research Organizations (CROs) are projected to witness the highest growth rate during the forecast period. This growth can be attributed to factors such as the growing trend of outsourcing of R&D activities by pharmaceutical and biotechnology companies to research organizations such as CROs. High throughput screening (HTS) allows CROs to rapidly screen large libraries of compounds against specific targets, making lead discovery more efficient. By identifying unsuitable compounds early, CROs can reduce costs and risks for their pharmaceutical clients, saving time and money and minimizing the risk of late-stage failures. CROs are investing in advanced HTS technologies and infrastructure, allowing them to perform complex screens not feasible for smaller companies. For instance, Labcorp Drug Development services use robotic screening systems, and Parexel integrates AI and machine learning with HTS to enhance their screening capabilities
"Drug Discovery segment accounted for the highest CAGR"
Based on application, the high-throughput screening (HTS) market is segmented into drug discovery, biochemical screening, life sciences research, and other applications. The drug discovery segment is projected to grow with the highest CAGR throughout 2024 to 2029. The key factor driving this segment's growth is the increasing prevalence of diseases leading to a rise in pharmaceutical drug discovery research and development. Pharmaceutical companies are utilizing this technology for lead discovery, target validation, primary screening, compound profiling, and hit identification Additionally, ongoing advancements such as automation and AI integration, in high-throughput screening (HTS) technologies further aid in making the drug discovery process more efficient and cost-effective supporting the growth of the market.
"Asia Pacific: The fastest-growing country in the high-throughput screening market"
The high-throughput screening (HTS) market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Factors such as rising pharmaceutical R&D spending, growing public-private partnerships, and increasing government funding drive the growth of the HTS market in this region.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side -80% and Demand Side - 20%
- By Designation: Managers -45%, CXOs and Directors -30%, and Executives - 25%
- By Region: North America-55%, Europe -15%, Asia-Pacific -15%, Latin America-10%, Middle East and Africa-5%
Lists of Companies Profiled in the Report:
- Thermo Fisher Scientific Inc. (US)
- Agilent Technologies, Inc. (US)
- Merck KGaA (Germany)
- Danaher Corporation (US)
- Revvity, Inc. (US)
- Tecan Group Ltd. (Switzerland)
- Bio-Rad Laboratories, Inc. (US)
- Corning Incorporated (US)
- Mettler-Toledo International Inc. (US)
- Lonza Group (Switzerland)
- Waters Corporation (US)
- Sartorius AG (Germany)
- Eppendorf SE (Germany)
- Porvair Plc (UK)
- Greiner AG (Austria)
- Charles River Laboratories (US)
- Eurofins Scientific (Luxembourg)
- Hamilton Company (US)
- Aurora Biomed Inc. (Canada)
- Gilson Incorporated (US)
- Brand GmbH+Co KG (Germany)
- BMG Labtech GmbH (Germany)
- DIANA Biotechnologies (Czechia)
- A.S. (Czech Republic)
- Creative Biolabs (US)
- HighRes Biosolutions (US)
- Biomat Srl, (Italy)
- Axxam S.p.A. (Italy)
- Sygnature Discovery Limited (UK)
- Crown Bioscience (US)
Research Coverage:
This report provides a detailed picture of the high throughput screening market. It aims at estimating the size and future growth potential of the market across different segments, such as offerings, technology, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Reasons to Buy the Report:
The report provides insights on the following pointers:
- Analysis of key drivers (the growing adoption of open innovative models in pharmaceutical & biotechnology companies, rising government funding and venture capital investments, increasing R&D spending, and technological advancements), restraints (high costs of using HTS instruments), opportunities (increasing adoption of HTS technologies in emerging markets, growing research on novel therapeutics and application of HTS technology in drug repurposing), and challenges (lack of skilled operators, and complexities in data management, assay development, and analysis) influencing the growth of the high throughput screening (HTS) market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the high throughput screening (HTS) market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various high-throughput screening opportunities and developments across key geographic regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the high-throughput screening (HTS) market.
- Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players like Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Revvity, Inc. (US), among others in the high-throughput screening market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.2.1 INCLUSIONS & EXCLUSIONS
- 1.3 MARKET SCOPE
- 1.3.1 SEGMENTS COVERED
- 1.3.2 REGIONS COVERED
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 LIMITATIONS
- 1.6 STAKEHOLDERS
- 1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.2 PRIMARY DATA
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 INSIGHTS FROM PRIMARIES
- 2.3 MARKET GROWTH FORECAST
- 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RISK ANALYSIS
- 2.7 RECESSION IMPACT ON HIGH-THROUGHPUT SCREENING (HTS) MARKET
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 HIGH-THROUGHPUT SCREENING (HTS) MARKET OVERVIEW
- 4.2 NORTH AMERICA: HIGH-THROUGHPUT SCREENING (HTS) MARKET SHARE, BY OFFERING AND COUNTRY (2023)
- 4.3 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
- 4.4 HIGH-THROUGHPUT SCREENING (HTS) MARKET SHARE, BY END USER, 2023
- 4.5 HIGH-THROUGHPUT SCREENING (HTS) MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Growing adoption of open innovation models
- 5.2.1.2 Rising government funding and venture capital investments
- 5.2.1.3 Increasing R&D spending
- 5.2.1.4 Technological advancements
- 5.2.2 RESTRAINTS
- 5.2.2.1 High cost of using HTS instruments
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Increasing adoption of HTS technologies in emerging markets
- 5.2.3.2 Growing research on novel therapeutics
- 5.2.3.3 Drug repurposing
- 5.2.4 CHALLENGES
- 5.2.4.1 Lack of skilled operators
- 5.2.4.2 Complexities in data management, assay development, and analysis
- 5.3 INDUSTRY TRENDS
- 5.3.1 ADOPTION OF PHENOTYPIC SCREENING
- 5.3.2 AUTOMATION AND AI INTEGRATION
- 5.3.3 RISE OF CRISPR TECHNOLOGY
- 5.3.4 INTEGRATION OF SINGLE-CELL ANALYSIS TECHNOLOGIES
- 5.3.5 REGULATORY CONSIDERATIONS
- 5.4 TECHNOLOGY ANALYSIS
- 5.4.1 KEY TECHNOLOGIES
- 5.4.1.1 High-content screening/analysis
- 5.4.1.2 Label-free detection (surface plasmon resonance)
- 5.4.2 COMPLEMENTARY TECHNOLOGIES
- 5.4.2.1 Microfluidics, organ-on-a-chip (OOC), and lab-on-a-chip (LOC)
- 5.4.2.2 Mass spectrometry (MS)
- 5.4.2.3 Flow cytometry
- 5.4.3 ADJACENT TECHNOLOGIES
- 5.4.3.1 Fragment-based drug discovery
- 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.6 PRICING ANALYSIS
- 5.7 VALUE CHAIN ANALYSIS
- 5.8 SUPPLY CHAIN ANALYSIS
- 5.9 ECOSYSTEM ANALYSIS
- 5.9.1 HIGH-THROUGHPUT SCREENING MARKET: ROLE OF RAW MATERIAL VENDORS
- 5.9.2 HIGH-THROUGHPUT SCREENING MARKET: ROLE OF PRODUCT & SERVICE PROVIDERS
- 5.9.3 HIGH-THROUGHPUT SCREENING MARKET: ROLE OF END USERS
- 5.9.4 HIGH-THROUGHPUT SCREENING MARKET: ROLE OF REGULATORY AUTHORITIES
- 5.1 PATENT ANALYSIS
- 5.11 TRADE ANALYSIS
- 5.11.1 IMPORT DATA FOR SPECTROMETERS
- 5.11.2 IMPORT DATA FOR MASS SPECTROMETERS
- 5.11.3 EXPORT DATA FOR SPECTROMETERS
- 5.11.4 EXPORT DATA FOR MASS SPECTROMETERS
- 5.12 REGULATORY ANALYSIS
- 5.12.1 REGULATORY LANDSCAPE
- 5.12.1.1 US
- 5.12.1.2 Europe
- 5.12.1.3 Emerging markets
- 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.13 PORTER'S FIVE FORCES ANALYSIS
- 5.13.1 INTENSITY OF COMPETITIVE RIVALRY
- 5.13.2 BARGAINING POWER OF SUPPLIERS
- 5.13.3 BARGAINING POWER OF BUYERS
- 5.13.4 THREAT OF SUBSTITUTES
- 5.13.5 THREAT OF NEW ENTRANTS
- 5.14 KEY CONFERENCES & EVENTS, 2024-2025
- 5.15 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS OF HIGH-THROUGHPUT SCREENING PRODUCTS & SERVICES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 5.15.2 BUYING CRITERIA FOR HIGH-THROUGHPUT SCREENING PRODUCTS & SERVICES
- 5.15.3 BUYING CRITERIA FOR HIGH-THROUGHPUT SCREENING PRODUCTS & SERVICES, BY END USER
6 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY OFFERING
- 6.1 INTRODUCTION
- 6.2 CONSUMABLES
- 6.2.1 REAGENTS & ASSAY KITS
- 6.2.1.1 Growing applications of HTS in drug discovery and life science research to support demand for consumables
- 6.2.2 LABORATORY CONSUMABLES
- 6.2.2.1 Growing automation in high-throughput screening to propel market growth
- 6.3 INSTRUMENTS
- 6.3.1 LIQUID HANDLING SYSTEMS
- 6.3.1.1 Ongoing technological advancements and automation to support market growth
- 6.3.2 DETECTION SYSTEMS
- 6.3.2.1 High demand for high-throughput and sensitive detection systems to propel market
- 6.3.3 IMAGING INSTRUMENTS
- 6.3.3.1 Advancements in high-content imaging systems to boost market
- 6.3.4 OTHER INSTRUMENTS
- 6.4 SERVICES
- 6.4.1 INCREASING ASSAY COMPLEXITIES AND GROWING NEED FOR COST-EFFECTIVE AND SPECIALIZED HTS EXPERTISE TO BOOST DEMAND
- 6.5 SOFTWARE
- 6.5.1 ONGOING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING SOFTWARE TOOLS TO DRIVE MARKET
7 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY APPLICATION
- 7.1 INTRODUCTION
- 7.2 DRUG DISCOVERY
- 7.2.1 GROWING DEMAND FOR MORE EFFECTIVE METHODS TO IDENTIFY NEW DRUG CANDIDATES TO SUPPORT MARKET GROWTH
- 7.3 BIOCHEMICAL SCREENING
- 7.3.1 GROWING AWARENESS OF GENETIC DISORDERS AND SCREENING TESTS TO BOOST MARKET GROWTH
- 7.4 LIFE SCIENCE RESEARCH
- 7.4.1 INCREASING INVESTMENTS IN STEM CELL RESEARCH TO CONTRIBUTE TO MARKET GROWTH
- 7.5 OTHER APPLICATIONS
8 HIGH-THROUGHPUT SCREENING MARKET, BY TECHNOLOGY
- 8.1 INTRODUCTION
- 8.2 CELL-BASED ASSAYS
- 8.2.1 2D CELL CULTURES
- 8.2.1.1 Cost-effectiveness of 2D cell cultures to promote market growth
- 8.2.2 3D CELL CULTURES
- 8.2.2.1 Scaffold-based technology
- 8.2.2.1.1 Hydrogels
- 8.2.2.1.1.1 Animal-derived hydrogels
8.2.2.1.1.1.1 Matrigel
8.2.2.1.1.1.1.1 Increasing applications of Matrigel in drug discovery and life science research to support market growth
8.2.2.1.1.1.2 Collagen
8.2.2.1.1.1.2.1 Growing demand for personalized medicines to support market growth
- 8.2.2.1.1.2 Synthetic hydrogels
8.2.2.1.1.2.1 Better consistency and low risk of contamination to increase adoption and drive growth
- 8.2.2.1.1.3 Alginate/Agarose
8.2.2.1.1.3.1 Ability of alginate to enhance accuracy and relevance to propel adoption
- 8.2.2.1.2 Inert matrices/Solid scaffolds
- 8.2.2.1.2.1 Lack of native-like microenvironment and other disadvantages to restrain growth
- 8.2.2.1.3 Micropatterned surfaces
- 8.2.2.1.3.1 Greater enzyme levels and drug reactivity to support adoption
- 8.2.2.2 Scaffold-free technology
- 8.2.2.2.1 Ultra-low-binding plates
- 8.2.2.2.1.1 Demand for high-quality, low-background assays to boost market
- 8.2.2.2.2 Hanging-drop plates
- 8.2.2.2.2.1 Cost-effectiveness to boost adoption among end users
- 8.2.2.2.3 Other scaffold-free technologies
- 8.2.3 REPORTER-BASED ASSAYS
- 8.2.3.1 Growing applications of gene expression to support growth
- 8.2.4 PERFUSION CELL CULTURES
- 8.2.4.1 Ongoing research to develop perfusion cell culture technology for drug discovery to support adoption
- 8.3 LAB-ON-A-CHIP
- 8.3.1 INCREASING APPLICATIONS OF LAB-ON-A-CHIP TECHNOLOGY FOR HTS AND PRECISION MEDICINE DEVELOPMENT TO SUPPORT MARKET GROWTH
- 8.4 LABEL-FREE TECHNOLOGY
- 8.4.1 ABILITY TO CONDUCT LABEL-FREE INVESTIGATION OF BIOMOLECULAR INTERACTIONS TO PROPEL ADOPTION
9 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY END USER
- 9.1 INTRODUCTION
- 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 9.2.1 GROWING DEMAND FOR HTS SOLUTIONS IN LEAD DISCOVERY TO SUPPORT MARKET GROWTH
- 9.3 ACADEMIC & RESEARCH INSTITUTES
- 9.3.1 GROWING ADOPTION OF HTS IN COLLABORATIVE ACADEMIC & RESEARCH ACTIVITIES TO AID MARKET GROWTH
- 9.4 CONTRACT RESEARCH ORGANIZATIONS (CROS)
- 9.4.1 INCREASING OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH FOR CROS
- 9.5 OTHER END USERS
10 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY REGION
- 10.1 INTRODUCTION
- 10.2 NORTH AMERICA
- 10.2.1 NORTH AMERICA: RECESSION IMPACT
- 10.2.2 US
- 10.2.2.1 Presence of major research institutes and key pharmaceutical companies to support market growth
- 10.2.3 CANADA
- 10.2.3.1 Government initiatives promoting research to support market growth
- 10.3 EUROPE
- 10.3.1 EUROPE: RECESSION IMPACT
- 10.3.2 GERMANY
- 10.3.2.1 Increasing research initiatives to boost market growth
- 10.3.3 UK
- 10.3.3.1 Investments by pharmaceutical sponsors for drug discovery to support market
- 10.3.4 FRANCE
- 10.3.4.1 Large pharmaceutical R&D expenditure to drive market growth
- 10.3.5 ITALY
- 10.3.5.1 Strong collaborative research networks to fuel growth
- 10.3.6 SPAIN
- 10.3.6.1 Rising R&D expenditure and increasing public-private partnerships to boost market
- 10.3.7 REST OF EUROPE
- 10.4 ASIA PACIFIC
- 10.4.1 ASIA PACIFIC: RECESSION IMPACT
- 10.4.2 CHINA
- 10.4.2.1 Growing research and collaborations in field of drug discovery to support growth of market
- 10.4.3 JAPAN
- 10.4.3.1 Growing focus on research and strategic collaborations to support market growth
- 10.4.4 INDIA
- 10.4.4.1 Developing healthcare industry and ongoing government initiatives to create favorable opportunities for market players
- 10.4.5 AUSTRALIA
- 10.4.5.1 Growing pharmaceutical industry to create favorable opportunities for market players
- 10.4.6 SOUTH KOREA
- 10.4.6.1 Growing pharmaceutical industry to favor market growth
- 10.4.7 REST OF ASIA PACIFIC (ROAPAC)
- 10.5 LATIN AMERICA
- 10.5.1 LATIN AMERICA: RECESSION IMPACT
- 10.5.2 BRAZIL
- 10.5.2.1 Gradual growth in research to contribute to growth
- 10.5.3 MEXICO
- 10.5.3.1 Favorable government support to contribute to growth
- 10.5.4 REST OF LATIN AMERICA
- 10.6 MIDDLE EAST
- 10.6.1 MIDDLE EAST: RECESSION IMPACT
- 10.6.2 GCC COUNTRIES
- 10.6.2.1 Saudi Arabia
- 10.6.2.1.1 Growing pharmaceuticals industry to support market growth
- 10.6.2.2 UAE
- 10.6.2.2.1 High R&D expenditure and advanced healthcare infrastructure to boost market growth
- 10.6.2.3 Rest of GCC Countries
- 10.7 AFRICA
- 10.7.1 INCREASING FUNDING AND PARTNERSHIPS IN RESEARCH SECTOR TO AID MARKET GROWTH
- 10.7.2 AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
- 11.1 OVERVIEW
- 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HIGH-THROUGHPUT SCREENING (HTS) MARKET
- 11.3 REVENUE ANALYSIS
- 11.4 MARKET SHARE ANALYSIS
- 11.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2023
- 11.5.1 STARS
- 11.5.2 EMERGING LEADERS
- 11.5.3 PERVASIVE PLAYERS
- 11.5.4 PARTICIPANTS
- 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 11.5.5.1 Company footprint
- 11.5.5.2 Offering footprint
- 11.5.5.3 Application footprint
- 11.5.5.4 Region footprint
- 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 11.6.1 PROGRESSIVE COMPANIES
- 11.6.2 RESPONSIVE COMPANIES
- 11.6.3 DYNAMIC COMPANIES
- 11.6.4 STARTING BLOCKS
- 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 11.7 COMPANY VALUATION & FINANCIAL METRICS
- 11.7.1 FINANCIAL METRICS
- 11.7.2 COMPANY VALUATION
- 11.8 BRAND/PRODUCT COMPARISON
- 11.9 COMPETITIVE SCENARIO
- 11.9.1 PRODUCT LAUNCHES
- 11.9.2 DEALS
- 11.9.3 EXPANSIONS
12 COMPANY PROFILES
- 12.1 KEY PLAYERS
- 12.1.1 THERMO FISHER SCIENTIFIC INC.
- 12.1.1.1 Business overview
- 12.1.1.2 Products & services offered
- 12.1.1.3 Recent developments
- 12.1.1.3.1 Product launches & approvals
- 12.1.1.3.2 Deals
- 12.1.1.3.3 Expansions
- 12.1.1.4 MnM view
- 12.1.1.4.1 Right to win
- 12.1.1.4.2 Strategic choices
- 12.1.1.4.3 Weaknesses & competitive threats
- 12.1.2 AGILENT TECHNOLOGIES, INC.
- 12.1.2.1 Business overview
- 12.1.2.2 Products & services offered
- 12.1.2.3 Recent developments
- 12.1.2.3.1 Product launches & upgrades
- 12.1.2.3.2 Deals
- 12.1.2.4 MnM view
- 12.1.2.4.1 Right to win
- 12.1.2.4.2 Strategic choices
- 12.1.2.4.3 Weaknesses & competitive threats
- 12.1.3 MERCK KGAA
- 12.1.3.1 Business overview
- 12.1.3.2 Products & services offered
- 12.1.3.3 Recent developments
- 12.1.3.3.1 Other developments
- 12.1.3.4 MnM view
- 12.1.3.4.1 Right to win
- 12.1.3.4.2 Strategic choices
- 12.1.3.4.3 Weaknesses & competitive threats
- 12.1.4 DANAHER CORPORATION
- 12.1.4.1 Business overview
- 12.1.4.2 Products & services offered
- 12.1.4.3 Recent developments
- 12.1.4.3.1 Product & service launches
- 12.1.4.3.2 Deals
- 12.1.4.3.3 Expansions
- 12.1.5 REVVITY, INC.
- 12.1.5.1 Business overview
- 12.1.5.2 Products & services offered
- 12.1.5.3 Recent developments
- 12.1.5.3.1 Product launches
- 12.1.5.3.2 Deals
- 12.1.6 TECAN GROUP LTD.
- 12.1.6.1 Business overview
- 12.1.6.2 Products & service offered
- 12.1.6.3 Recent developments
- 12.1.6.3.1 Product launches & upgrades
- 12.1.6.3.2 Deals
- 12.1.7 BIO-RAD LABORATORIES, INC.
- 12.1.7.1 Business overview
- 12.1.7.2 Products & services offered
- 12.1.7.3 Recent developments
- 12.1.7.3.1 Product launches
- 12.1.8 CORNING INCORPORATED
- 12.1.8.1 Business overview
- 12.1.8.2 Products & services offered
- 12.1.8.3 Recent developments
- 12.1.8.3.1 Product launches
- 12.1.9 METTLER-TOLEDO INTERNATIONAL INC.
- 12.1.9.1 Business overview
- 12.1.9.2 Products & services offered
- 12.1.9.3 Recent developments
- 12.1.9.3.1 Product launches
- 12.1.10 LONZA GROUP
- 12.1.10.1 Business overview
- 12.1.10.2 Products & services offered
- 12.1.10.3 Recent developments
- 12.1.11 WATERS CORPORATION
- 12.1.11.1 Business overview
- 12.1.11.2 Products & services offered
- 12.1.11.3 Recent developments
- 12.1.11.3.1 Product launches
- 12.1.11.3.2 Deals
- 12.1.12 SARTORIUS AG
- 12.1.12.1 Business overview
- 12.1.12.2 Products & services offered
- 12.1.12.3 Recent developments
- 12.1.12.3.1 Product launches
- 12.1.13 EPPENDORF SE
- 12.1.13.1 Business overview
- 12.1.13.2 Products & services offered
- 12.1.13.3 Recent developments
- 12.1.13.3.1 Deals
- 12.1.13.3.2 Expansions
- 12.1.14 PORVAIR PLC
- 12.1.14.1 Business overview
- 12.1.14.2 Products & services offered
- 12.1.15 GREINER AG
- 12.1.15.1 Business overview
- 12.1.15.2 Products & services offered
- 12.1.16 CHARLES RIVER LABORATORIES
- 12.1.16.1 Business overview
- 12.1.16.2 products & services offered
- 12.1.16.3 Recent developments
- 12.1.17 EUROFINS SCIENTIFIC
- 12.1.17.1 Business overview
- 12.1.17.2 Products & services offered
- 12.1.17.3 Recent developments
- 12.1.17.3.1 Service launches
- 12.1.17.3.2 Deals
- 12.1.17.3.3 Expansions
- 12.1.18 HAMILTON COMPANY
- 12.1.18.1 Business overview
- 12.1.18.2 Products & services offered
- 12.1.18.3 Recent developments
- 12.1.18.3.1 Product launches
- 12.1.18.3.2 Deals
- 12.1.19 AURORA BIOMED INC.
- 12.1.19.1 Business overview
- 12.1.19.2 Products & services offered
- 12.1.20 GILSON INCORPORATED
- 12.1.20.1 Business overview
- 12.1.20.2 Products & services offered
- 12.1.20.3 Recent developments
- 12.1.20.3.1 Product launches
- 12.1.20.3.2 Deals
- 12.1.21 BRAND GMBH + CO KG
- 12.1.21.1 Business overview
- 12.1.21.2 Products & services offered
- 12.1.21.3 Recent developments
- 12.2 OTHER PLAYERS
- 12.2.1 BMG LABTECH GMBH
- 12.2.2 DIANA BIOTECHNOLOGIES, A.S.
- 12.2.3 CREATIVE BIOLABS
- 12.2.4 HIGHRES BIOSOLUTIONS
- 12.2.5 BIOMAT SRL
- 12.2.6 AXXAM S.P.A.
- 12.2.7 SYGNATURE DISCOVERY LIMITED
- 12.2.8 CROWN BIOSCIENCE
13 APPENDIX
- 13.1 DISCUSSION GUIDE
- 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 13.3 CUSTOMIZATION OPTIONS
- 13.4 RELATED REPORTS
- 13.5 AUTHOR DETAILS
